PMID- 28331127
OWN - NLM
STAT- MEDLINE
DCOM- 20170410
LR  - 20230928
IS  - 1880-9952 (Electronic)
IS  - 1346-4280 (Print)
IS  - 1346-4280 (Linking)
VI  - 56
IP  - 3
DP  - 2017
TI  - The Impact of a Humanized CCR4 Antibody (Mogamulizumab) on Patients with 
      Aggressive-Type Adult T-Cell Leukemia-Lymphoma Treated with Allogeneic 
      Hematopoietic Stem Cell Transplantation.
PG  - 135-144
LID - 10.3960/jslrt.56.135 [doi]
AB  - Although a humanized CCR4 antibody (mogamulizumab) was reported to be effective 
      for refractory adult T-cell leukemia-lymphoma (ATL), several reports regarding 
      the use of mogamulizumab before allo-hematopoietic stem cell transplantation 
      (HSCT) strongly indicated a high incidence of severe acute 
      graft-versus-host-disease (GVHD) and treatment-related mortality (TRM). We 
      retrospectively analyzed nine aggressive-type ATL patients who underwent 
      allo-HSCT at a single institution in Miyazaki from 2006.1.1 to 2015.7.31. Among 
      nine ATL patients, three had used mogamulizumab before treatment with allo-HSCT 
      because of the poor control of refractory ATL. All three patients were treated 
      with four to eight cycles of mogamulizumab. The interval from last administration 
      of mogamulizumab to allo-HSCT was two to five months. All three patients with 
      prior mogamulizumab treatment developed mild-moderate acute GVHD (grade 2) 28, 
      34, or 40 days after allo-HSCT. Acute GVHD was controlled by prednisolone 
      treatment. Two patients in complete remission before allo-HSCT exhibited 
      relatively prolonged survival (survival rate, 66%). Moreover, one patient 
      developed human T-cell leukemia virus type 1-associated myelopathy-mimicking 
      myelitis at five months after allo-HSCT. In contrast, two of six ATL patients 
      without a history of mogamulizumab use survived (survival rate 33%). Thus, in 
      cases of mogamulizumab use before treatment with allo-HSCT for refractory ATL, an 
      appropriately long interval from the last administration of mogamulizumab to 
      allo-HSCT may be one of factors to reduce TRM by acute GVHD, and to subsequently 
      enhance graft-versus-tumor effects in ATL cases. Furthermore, caution is needed 
      when administering mogamulizumab before allo-HSCT for severe GVHD and TRM.
FAU - Kawano, Noriaki
AU  - Kawano N
AD  - Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital.
FAU - Kuriyama, Takuro
AU  - Kuriyama T
FAU - Yoshida, Shuro
AU  - Yoshida S
FAU - Kawano, Sayaka
AU  - Kawano S
FAU - Yamano, Yoshihisa
AU  - Yamano Y
FAU - Marutsuka, Kousuke
AU  - Marutsuka K
FAU - Minato, Seiichirou
AU  - Minato S
FAU - Yamashita, Kiyoshi
AU  - Yamashita K
FAU - Ochiai, Hidenobu
AU  - Ochiai H
FAU - Shimoda, Kazuya
AU  - Shimoda K
FAU - Ishikawa, Fumihiko
AU  - Ishikawa F
FAU - Kikuchi, Ikuo
AU  - Kikuchi I
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Clin Exp Hematop
JT  - Journal of clinical and experimental hematopathology : JCEH
JID - 101141257
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - YI437801BE (mogamulizumab)
SB  - IM
MH  - Adult
MH  - Allografts
MH  - Antibodies, Monoclonal, Humanized/*adverse effects/therapeutic use
MH  - Female
MH  - Graft vs Host Disease/*chemically induced
MH  - Hematopoietic Stem Cell Transplantation/*adverse effects/methods
MH  - Humans
MH  - Leukemia-Lymphoma, Adult T-Cell/complications/mortality/*therapy
MH  - Male
MH  - Middle Aged
MH  - Remission Induction
MH  - Retrospective Studies
MH  - Salvage Therapy/adverse effects/methods
MH  - Survival Rate
MH  - Time Factors
PMC - PMC6144179
COIS- CONFLICT OF INTEREST: The authors state that they have no conflict of interest.
EDAT- 2017/03/24 06:00
MHDA- 2017/04/11 06:00
PMCR- 2017/03/22
CRDT- 2017/03/24 06:00
PHST- 2017/03/24 06:00 [entrez]
PHST- 2017/03/24 06:00 [pubmed]
PHST- 2017/04/11 06:00 [medline]
PHST- 2017/03/22 00:00 [pmc-release]
AID - 56-135 [pii]
AID - 10.3960/jslrt.56.135 [doi]
PST - ppublish
SO  - J Clin Exp Hematop. 2017;56(3):135-144. doi: 10.3960/jslrt.56.135.